Metoclopramide is a well-established medication primarily used to treat gastrointestinal motility disorders and to prevent nausea and vomiting. As a dopamine receptor antagonist with additional serotonin receptor modulating properties, it exerts its effects both centrally and peripherally. Developed in the 1960s, metoclopramide has become a staple in gastroenterology and oncology, though its use is tempered by a significant risk of neurological adverse effects, particularly with long-term or high-dose administration.

Pharmacology and Mechanism of Action

Metoclopramide acts as a competitive antagonist at dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema, thereby reducing nausea and vomiting. It also blocks D2 receptors in the upper gastrointestinal tract, 130mg (http://herbodieteticaninakrisso.es/) leading to increased lower esophageal sphincter tone, enhanced gastric peristalsis, and accelerated gastric emptying. Additionally, metoclopramide has weak agonist activity at serotonin 5-HT4 receptors and antagonist activity at 5-HT3 receptors, which contribute to its prokinetic effects. The drug is rapidly absorbed after oral administration, with oral bioavailability ranging from 30% to 100% due to first-pass metabolism. It crosses the blood-brain barrier and is eliminated primarily by the kidneys, with a half-life of about 5–6 hours.

Indications

Metoclopramide is indicated for several clinical conditions:

1. Gastroparesis: It is a first-line therapy for diabetic gastroparesis and other forms of delayed gastric emptying. By improving antral contractions and coordinating antroduodenal motility, metoclopramide alleviates symptoms such as early satiety, postprandial fullness, nausea, and vomiting.
2. 
   
3. 
   
4. Nausea and Vomiting: It is used to treat nausea and vomiting induced by chemotherapy, radiation therapy, surgery, and migraines. For chemotherapy-induced nausea, it is often used in combination with other antiemetics, particularly for moderately emetogenic regimens.
5. 
   
6. 
   
7. Gastroesophageal Reflux Disease (GERD): While proton pump inhibitors are the mainstay, metoclopramide may be used adjunctively in patients with refractory GERD to increase lower esophageal sphincter pressure and enhance esophageal clearance.
8. 
   
9. 
   
10. Lactation Stimulation: Off-label, metoclopramide has been used to enhance breast milk production by increasing prolactin secretion, though this use is controversial and not widely recommended due to safety concerns.
11. 
    
12. 
    

Metoclopramide is contraindicated in patients with a history of tardive dyskinesia, pheochromocytoma, gastrointestinal hemorrhage, mechanical obstruction or perforation, and seizure disorders. It should be used with caution in patients with Parkinson's disease, as it can worsen symptoms by blocking dopamine receptors. Renal impairment reduces clearance, necessitating dose adjustments in moderate to severe chronic kidney disease. The drug is also avoided in patients with a history of depression, as it may exacerbate psychiatric conditions.

Adverse Effects

The most concerning adverse effects involve the central nervous system. Acute dystonic reactions, such as torticollis, oculogyric crisis, and trismus, can occur, especially in children and young adults. Parkinsonian symptoms (tremor, rigidity, bradykinesia) are more common in elderly patients with prolonged use. Tardive dyskinesia, a potentially irreversible movement disorder, is associated with cumulative doses and long-term therapy—hence the FDA black box warning limiting use to short durations (usually ≤12 weeks). Other side effects include drowsiness, fatigue, restlessness, and akathisia. Endocrine effects such as hyperprolactinemia (causing galactorrhea, gynecomastia, and menstrual irregularities) occur due to dopamine antagonism in the pituitary. Metoclopramide can also cause methemoglobinemia in neonates, particularly in premature infants, due to reduced NADH-cytochrome b5 reductase activity.

Dosage and Administration

Typical adult doses for gastroparesis and GERD range from 5 to 10 mg taken orally 30 minutes before meals and at bedtime. For chemotherapy-induced nausea, higher doses (up to 2 mg/kg intravenously) are used, often with prophylactic diphenhydramine to prevent dystonic reactions. In pediatric practice, doses are weight-based (0.1–0.2 mg/kg per dose), but use is limited due to safety concerns. Therapy should not exceed 12 weeks except in specific, carefully monitored situations. Intravenous administration requires slow infusion to avoid transient hypertension and cardiac arrhythmias.

Drug Interactions

Metoclopramide interacts with several medications. Anticholinergic agents (e.g., atropine, benztropine) can antagonize its prokinetic effects. CNS depressants (alcohol, benzodiazepines, opioids) potentiate sedation. Dopaminergic antagonists (antipsychotics, other antiemetics) increase the risk of extrapyramidal symptoms. MAO inhibitors may cause hypertensive crises, and cyclosporine levels may be altered due to changes in gastric emptying. Additionally, metoclopramide can reduce the absorption of drugs that rely on gastric residence time (e.g., digoxin, levodopa) while increasing the absorption of others (e.g., acetaminophen).

Special Populations

In pregnancy, metoclopramide is classified as FDA Category B; available data suggest no increased risk of major malformations, but it is generally reserved for cases of severe hyperemesis gravidarum unresponsive to first-line agents. It is excreted in breast milk in small amounts, and short-term maternal use is considered compatible with breastfeeding, though monitoring for infant side effects is advised. Elderly patients are more susceptible to Parkinsonian side effects and tardive dyskinesia; therefore, the lowest effective dose for the shortest duration should be used.

Clinical Considerations and Alternatives

Given the risk of tardive dyskinesia, metoclopramide is now considered a second-line agent for many conditions. Alternatives for gastroparesis include domperidone (a peripheral D2 antagonist not available in many countries), erythromycin (a motilin agonist used short-term), and pyloric botulinum toxin injection. For nausea and vomiting, 5-HT3 antagonists (ondansetron), NK1 receptor antagonists (aprepitant), and corticosteroids are often preferred in the oncology setting. In postoperative nausea, multimodal prophylaxis is common.

Conclusion

Metoclopramide remains a valuable pharmacological tool for managing gastrointestinal dysmotility and nausea, particularly when other agents fail or are unavailable. Its efficacy is well documented, but the potential for serious neurological adverse effects demands careful patient selection, short-term use, and thorough monitoring. Clinicians should be vigilant for early signs of movement disorders and educate patients accordingly. With proper stewardship, metoclopramide can provide significant benefit while minimizing harm.